TIC10/ONC201 synergizes with Bcl-2/Bcl-xL inhibition in glioblastoma by suppression of Mcl-1 and its binding partners in vitro and in vivo

This publication has 54 references indexed in Scilit:

• ABT-737 promotes tBid mitochondrial accumulation to enhance TRAIL-induced apoptosis in glioblastoma cells
  Cell Death & Disease, 2012
• Targeting the B-Cell Lymphoma/Leukemia 2 Family in Cancer
  Journal of Clinical Oncology, 2012
• Bcl-2 is a better ABT-737 target than Bcl-xL or Bcl-w and only Noxa overcomes resistance mediated by Mcl-1, Bfl-1, or Bcl-B
  Cell Death & Disease, 2012
• Mcl-1 Phosphorylation Defines ABT-737 Resistance That Can Be Overcome by Increased NOXA Expression in Leukemic B cells
  Cancer Research, 2012
• Lapatinib and Obatoclax Kill Tumor Cells through Blockade of ERBB1/3/4 and through Inhibition of BCL-xL and MCL-1
  Molecular Pharmacology, 2012
• BAG3 Protein Is Overexpressed in Human Glioblastoma and Is a Potential Target for Therapy
  The American Journal of Pathology, 2011
• Exploiting the mitochondrial unfolded protein response for cancer therapy in mice and human cells
  Journal of Clinical Investigation, 2011
• Navitoclax, a targeted high-affinity inhibitor of BCL-2, in lymphoid malignancies: a phase 1 dose-escalation study of safety, pharmacokinetics, pharmacodynamics, and antitumour activity
  The Lancet Oncology, 2010
• A novel BH3 ligand that selectively targets Mcl-1 reveals that apoptosis can proceed without Mcl-1 degradation
  Journal of Cell Biology, 2008
• Radiotherapy plus Concomitant and Adjuvant Temozolomide for Glioblastoma
  New England Journal of Medicine, 2005